September 8, 2026

Therapy to Watch: Hereditary Angioedema PDUFA Date

Intellia Therapeutics has announced that the FDA has accepted its Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). The FDA granted Priority Review and set a Prescription Drug User Fee Act (PDUFA) date of March 10, 2027.

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license?utm_content=385521070&utm_medium=social&utm_source=linkedin&hss_channel=lcp-37897480

» More News